FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2551111897> ?p ?o ?g. }

• W2551111897 abstract "Abstract Background: Post transplant lymphoproliferative disorder (PTLD), especially primary CNS lymphoma (PCNSL), is a serious complication of solid organ transplantation. Treatment has proved difficult and includes dose reduction of immune suppression (RIS), combination chemotherapy and radiotherapy. Recently the monoclonal antibody Rituximab, has been added to the therapeutic choice. Chemotherapy used in PCNSL is based on high-dose methotrexate (HDMTX), but need to be carefully monitored in adult patients (pts), especially with renal transplant. HDMTX could be associated with deleterious effects on renal graft function. We report here the results of HDMTX in pts with PCNSL after solid organ transplantation treated at the Institut de Cancérologie Gustave Roussy. Methods: From February 2000, 18 pts with PTLD were referred to our Institute. 9 of them had PCNSL following renal (6), hepatic (1) or both renal and pancreatic (2) transplants. In all cases, RIS was not associated with PCNSL regression. Except in one case, all pts were treated with chemotherapy with HDMTX in 3-hour infusion. Folinic acid rescue was given IV every 6 hours (50 mg/m2) combined with alkaline hyper-hydration until MTX serum level was below 1 X 10–7 M. Immune suppressive therapy (IST) was reduced to solupred (10 mg/day) during chemotherapy and was reduced for 8 months after chemotherapy. 4 cycles of chemotherapy was planned and efficacy assessed every two cycles. If CR was reached with chemotherapy alone, no radiotherapy was delivered. Results: From March 2007, 9 pts (4 males) developed PCNSL with a median of 6 years after transplant (1–26 years). Median age was 55 (range 33–70). PS was > 2 in 8/9 and 3 in one case. 8/9 pts had glomerular filtration rate > 60 ml/mn and received HDMTX without renal toxicity. One pt with GFR < 60 ml/mn was treated with 3 cycles of HD cytarabine + rituximab and adryamicin and is alive in complete remission (CR) 31 months after therapy. With a median follow up of 15 months, 4/9 pts are alive and in CR 45, 31, 29 and 7 months after therapy. 3 of them received radiotherapy. 5 pts died, 2 of lymphoma progression, 2 of chemotherapy toxicity (sepsis) and one of a gastric cancer. No graft rejection was observed. Conclusions: our results suggest HDMTX can be given in pts with PCNSL and long term CR can be reached without graft failure. As chemotherapy regimens used for in those pts are in themselves immunosuppressive, IST may be reduced during chemotherapy without major risk." @default.
• W2551111897 created "2016-11-30" @default.
• W2551111897 creator A5006656210 @default.
• W2551111897 creator A5008073796 @default.
• W2551111897 creator A5032462496 @default.
• W2551111897 creator A5033149886 @default.
• W2551111897 creator A5034569251 @default.
• W2551111897 creator A5038511140 @default.
• W2551111897 creator A5051162453 @default.
• W2551111897 date "2008-11-16" @default.
• W2551111897 modified "2023-09-28" @default.
• W2551111897 title "High-Dose Methotrexate and Cytarabine Chemotherapy May Be Effective and Safe in Solid Organ Transplant Recipients with Primary CNS Lymphomas (PCNSL)" @default.
• W2551111897 doi "https://doi.org/10.1182/blood.v112.11.3611.3611" @default.
• W2551111897 hasPublicationYear "2008" @default.
• W2551111897 type Work @default.
• W2551111897 sameAs 2551111897 @default.
• W2551111897 citedByCount "2" @default.
• W2551111897 crossrefType "journal-article" @default.
• W2551111897 hasAuthorship W2551111897A5006656210 @default.
• W2551111897 hasAuthorship W2551111897A5008073796 @default.
• W2551111897 hasAuthorship W2551111897A5032462496 @default.
• W2551111897 hasAuthorship W2551111897A5033149886 @default.
• W2551111897 hasAuthorship W2551111897A5034569251 @default.
• W2551111897 hasAuthorship W2551111897A5038511140 @default.
• W2551111897 hasAuthorship W2551111897A5051162453 @default.
• W2551111897 hasConcept C126322002 @default.
• W2551111897 hasConcept C126894567 @default.
• W2551111897 hasConcept C141071460 @default.
• W2551111897 hasConcept C143998085 @default.
• W2551111897 hasConcept C2776694085 @default.
• W2551111897 hasConcept C2778041864 @default.
• W2551111897 hasConcept C2778336483 @default.
• W2551111897 hasConcept C2779338263 @default.
• W2551111897 hasConcept C2779804826 @default.
• W2551111897 hasConcept C2780456651 @default.
• W2551111897 hasConcept C2780653079 @default.
• W2551111897 hasConcept C2781059491 @default.
• W2551111897 hasConcept C2781173314 @default.
• W2551111897 hasConcept C2911091166 @default.
• W2551111897 hasConcept C71924100 @default.
• W2551111897 hasConcept C90924648 @default.
• W2551111897 hasConceptScore W2551111897C126322002 @default.
• W2551111897 hasConceptScore W2551111897C126894567 @default.
• W2551111897 hasConceptScore W2551111897C141071460 @default.
• W2551111897 hasConceptScore W2551111897C143998085 @default.
• W2551111897 hasConceptScore W2551111897C2776694085 @default.
• W2551111897 hasConceptScore W2551111897C2778041864 @default.
• W2551111897 hasConceptScore W2551111897C2778336483 @default.
• W2551111897 hasConceptScore W2551111897C2779338263 @default.
• W2551111897 hasConceptScore W2551111897C2779804826 @default.
• W2551111897 hasConceptScore W2551111897C2780456651 @default.
• W2551111897 hasConceptScore W2551111897C2780653079 @default.
• W2551111897 hasConceptScore W2551111897C2781059491 @default.
• W2551111897 hasConceptScore W2551111897C2781173314 @default.
• W2551111897 hasConceptScore W2551111897C2911091166 @default.
• W2551111897 hasConceptScore W2551111897C71924100 @default.
• W2551111897 hasConceptScore W2551111897C90924648 @default.
• W2551111897 hasLocation W25511118971 @default.
• W2551111897 hasOpenAccess W2551111897 @default.
• W2551111897 hasPrimaryLocation W25511118971 @default.
• W2551111897 hasRelatedWork W1608441558 @default.
• W2551111897 hasRelatedWork W2049616201 @default.
• W2551111897 hasRelatedWork W2101437058 @default.
• W2551111897 hasRelatedWork W2125990591 @default.
• W2551111897 hasRelatedWork W2131289635 @default.
• W2551111897 hasRelatedWork W2353584562 @default.
• W2551111897 hasRelatedWork W2365811944 @default.
• W2551111897 hasRelatedWork W2558780974 @default.
• W2551111897 hasRelatedWork W2560391779 @default.
• W2551111897 hasRelatedWork W2572915367 @default.
• W2551111897 hasRelatedWork W2588426502 @default.
• W2551111897 hasRelatedWork W2594858323 @default.
• W2551111897 hasRelatedWork W2619812087 @default.
• W2551111897 hasRelatedWork W2626638450 @default.
• W2551111897 hasRelatedWork W2753841411 @default.
• W2551111897 hasRelatedWork W2791301250 @default.
• W2551111897 hasRelatedWork W2911460658 @default.
• W2551111897 hasRelatedWork W2980670405 @default.
• W2551111897 hasRelatedWork W3030613544 @default.
• W2551111897 hasRelatedWork W3089038223 @default.
• W2551111897 isParatext "false" @default.
• W2551111897 isRetracted "false" @default.
• W2551111897 magId "2551111897" @default.
• W2551111897 workType "article" @default.